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Synchronous caecal small-cell neuroendocrine carcinoma and            
adenocarcinoma of the rectum 
 
Sinkroni neuroendokrini karcinom malih stanica cekuma i adenokarcinom rektuma 
 







Small-cell neuroendocrine colon carcinoma is a rare entity with a usually poor prognosis. An 80-year-old 
female had colon cancer surgery due to synchronous tumour of the rectum and caecum. Pathohystological 
analysis of the caecal tumour showed trabecular and solid clusters, relatively uniformed small to middle 
sized epithelial cells, deficient cytoplasm and there were a great number of mitosis with larger areas of 
necrosis in the connective tissue. The immunohistochemistry was positive for chromogranin A. The caecal 
tumour was diagnosed as a small-cell neuroendocrine carcinoma. In addition, the rectal tumour showed 
microscopic findings consistent with stage IIA adenocarcinoma. The immunohistochemical panel showed 
that the tumour was negative for neuroendocrine markers. There were no clinical findings suggestive of 
hormone hypersecretion. Cancer metastases were not found. Postoperative chemotherapy was applied. The 
patient is still alive, in good general condition and with no signs of tumour progression. 




Neuroendokrini karcinom malih stanica debeloga crijeva rijedak je entitet s najčešće lošom prognozom. 
Osamdesetogodišnja žena podvrgnuta je operaciji debeloga crijeva zbog sinkronog tumora rektuma i 
cekuma. Patohistološka analiza tumora cekuma pokazala je trabekularne i čvrste nakupine, relativno 
uniformne male do srednje velike epitelne stanice, oskudne citoplazme, a u vezivnom tkivu bilo je dosta 
mitoza s većim područjima nekroze. Imunohistokemija je bila pozitivna na kromogranin A. Tumor je 
dijagnosticiran kao neuroendokrini karcinom malih stanica cekuma. Osim toga, tumor rektuma pokazao je 
mikroskopske nalaze u skladu s IIA stadijem adenokarcinoma. Imunohistokemijski panel pokazao je da je 
tumor bio negativan na neuroendokrine markere. Nije bilo kliničkoga nalaza koji ukazuje na pojačanu 
sekreciju hormona. Metastaze karcinoma nisu nađene. Provedena je postoperativna kemoterapija. 
Pacijentica je i dalje živa, dobrog općega stanja, bez znakova progresije tumora. 
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Introduction 
 
Neuroendocrine carcinomas are malignant tumours 
that show histopathological and immunohistochemical 
evidence of neuroendocrine differentiation. Neuro-
endocrine tumours can develop at many different sites 
of the body, but colon is a very rare site.
1
 Most 
neuroendocrine tumours are carcinoids and they have 
a better prognosis than conventional adenocarci-
nomas. The original term “carcinoid” equates to 
neuroendocrine tumours that are both grade 1 and 2 
(well differentiated), whereas grade 3 neuroendocrine 
tumours are mostly small-cell neuroendocrine 
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carcinomas (SCNEC) with a minority component 
being large-cell type (poorly differentiated).
2
 Small-
cell neoplasia most commonly originates in the lung 
but also other sites such as skin, thymus, kidney, 
breast, ovary, uterus, urinary bladder, hepatobiliary 
tree, pancreas and salivary glands.
3
 More specifically, 





all colonic cancers and is considered to be an 
aggressive neoplasm with rapid growth and early 






An 80-year-old female was admitted with leading 
symptom of abdominal discomfort. Patient's past 
medical history was unremarkable. In the last four 
months the patient is periodically experiencing upper 
abdominal pain and loss of appetite, denying nausea 
and vomiting. In the same period of time she lost 20 
kg of weight. In the last four months patient's stool is 
irregular (absent from time to time in periods of 8 
days) with occasional diarrhea without tinge of blood 
or melena. The laboratory results verify microcytic 
anemia. 
Colonoscopy has showed a tumorous mass in the 
mid third of rectum. Irigography has verified a lack in 
filling measured 40 mm in diametar, in the area of 
rectosigmoid crossing, which is considerably reducing 
the lumen of the bowel and where the barium enema 
isn't passing through. Computed tomography (CT) of 
the abdomen and pelvis has shown a thickening of the 
bowel wall which was highly suspect of an infiltration 
of the rectal ampulle on the left side just above the 
anocutaneous border, and just above the same 
rectosigmoid area near the back bowel wall has 
shown a round tumorous mass 5 cm in diameter 
(Picture 1). The wall of the caecum was slightly 
thicker (Picture 2). The pelvic CT showed no enlarged 
lymphatic nodes. 
On the third day of patient's hospitalization, based 
upon diagnostic criteria, we decide to perform a 
medial laparotomy which has shown a smaller tumour 
mesaured 5 cm in diameter in the mid third of rectum. 
Right hemicolectomy with the resection of infiltrated 
ileum was performed and the Hartmann procedure               
in the rectosigmoidal area. The recovery was 
unremarkable. The patient was discharged 12 days 





Picture 1 CT finding of the abdomen and pelvis. Tumorous mass in the rectum (arrow) 
Slika 1. CT nalaz abdomena i zdjelice. Tumorska masa u rektumu (strelica) 
 





Picture 2 CT finding of the abdomen and pelvis. Thickened caecal wall caused by                                                      
giant small cell neuroendocrine carcinoma (arrows) 
Slika 2. CT nalaz abdomena i zdjelice. Zadebljanje stijenke cekuma uzrokovano                                                      
velikim neuroendokrinim karcinomom malih stanica (strelice) 
 
 
The macroscopic examination has shown, in the 
area of the Bauchin's valve, caecum and ascendant 
colon on a length of 8.5 cm, a yellowish white 
tumorous tissue that engages the whole circum-
ferention of the bowel (Picture 3). This tumour 
involved the pericolic adipose tissue. The rectum 
margin was free from tumour. Metastasis was found 
in neither of eleven dissected regional lymph nodes. 
The histological examination has shown that the 
tissue in question was a cluster of trabecular and 
solid, relatively uniformed small to middle sized 
epithelial cells with deficient cytoplasm and in the 
connective tissue were a lot of mitosis (up to 100 per 
10 high power field) with larger areas of necrosis. An 
immunohistochemical panel was performed, and the 
tumour was found to be positive for chromogranin A. 
The synaptophysin and CD56 was negative. 
Therefore, our diagnosis of the tumour was a giant 
small-cell neuroendocrine carcinoma (Picture 4). 
The macroscopic examination of the second 
sample, a part of rectosigmoid colon, has shown an 
exophytic tumour sized 4.5 x 2 cm, which engages 
the whole circumferention of bowel (Picture 5). All 
sampled lymph nodes and surgical ends were free of 
tumour involvement. The tumour is histologically 
made of atypical glandular formations coated with 
malignant epithelium partly making a cribriform 
form. The tumorous tissue infiltrates the whole 
thickness of the bowel wall and spreading to the 
under laying fat tissue. Diagnosis was stage IIA 
adenocarcinoma. On the immunohistochemical 
staining panel, the tumour was negative for neuro-
endocrine markers (chromogranin A, synaptophysin 
and CD56). Thus, we concluded that the patient had 
synchronous a primary adenocarcinoma of the rectum 
and a primary giant SCNEC in the caecum. The 
patient received postoperative chemotherapy with 5-
fluorouracil. Five cycles of chemotherapy were 
performed. The patient is still alive and with no sign 
of tumour progression or distant metastasis 6 month 
after the treatment. In the follow up of patient we 
determined carcinoembryonic antigen (CEA), 
performed liver ultrasound and control thorax-
abdomen-pelvis CT. 






Picture 3 Giant yellowish white neuroendocrine carcinoma in the caecum (arrow) 




Picture 4 Microscopic finding. Immunohistochemical staining revealed positive findings for chromogranin A. 
Slika 4. Mikroskopski nalaz. Imunohistokemijsko bojenje pokazalo je pozitivan nalaz na kromogranin A. 





Picture 5 Macroscopic appearance of the resected specimen. Exophytic adenocarcinoma in the rectum (arrow). 





This case has two aspects of clinical interest. First, 
synchronous adenocarcinoma and SCNEC is the rare 
appearance in clinical practice. Second, there are no 
clear guidelines for appropriate treatment and follow 
up of SCNEC with a synchronous secondary 
malignancy; therefore, our experience may help in the 
consideration of treatment for similar patients. 
SCNEC are rare in the large bowel, but more 
common in this location than elsewhere in the inte-
stines. Neuroendocrine carcinomas including SCNECs 
comprise approximately 0.6% of all carcinomas of the 
large bowel.
6
 The average age of patients with 
neuroendocrine carcinomas of the large bowel is 61.5 
years and the male-to-female ratio is essentially 1 : 1, 
similar to the values for large-bowel adenocarci-
nomas.
6,7
 Neuroendocrine carcinomas of the colo-
rectum are grossly similar to convectional 
adenocarcinomas. If an associated adenoma is 
present, they may be polypoid; if not, they are 
typically ulcerated neoplasms with a raised border, 
and on cut section they are infiltrative. SCNEC is a 
neuroendocrine tumour that has features in common 
with neuroendocrine-differentiated tumours as well as 
specific cytological features: small cells with minimal 
cytoplasm and fusiform nuclei and have very high 
mitotic rate, averaging 65 per 10 high power field.
8
 
Small cell carcinomas typically express chromogranin 
A, synaptophysin and CD56.
9
 In the report by 
Vilallonga et al.,
10
 on neuroendocrine tumours, 
excluding carcinoid tumours, most patients presented 
with a paraneoplastic or carcinoid syndrome. 
However, our patient had no such symptoms. 
However, we cannot rule out the possibility of 
secreted hormones in the plasma at very low 
concentrations not associated with a clinical 
syndrome, or if there were secreted peptides they 
were not associated with clinical effects. The precise 
pathogenesis of secondary cancers with neuro-
endocrine carcinoma remains unclear. Some reports 
have suggested that neuroendocrine tumours occur as 
secondary primary carcinoma. According to one 
previous study, gastrin and cholecystokinin were 
associated with neuroendocrine carcinoma; this 
resulted in tissue growth in the gastrointestinal tract 
and carcinogenesis leading to colorectal and gastric 
cancer.
11
 In addition, Prommeger et al.
12
 reported that 
neuroendocrine tumours are associated with a high 
risk of secondary gastrointestinal malignancy. They 
studied 96 patients with neuroendocrine tumours and 
found that 14 patients had a neuroendocrine tumours 
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and a second primary malignancy. Five patients had a 
synchronous second primary malignancy. The 
locations were two colon cancers with one double 
colon cancer, one gastric cancer, one bladder cancer, 
and one ovarian cancer. In recent study Kato et al.
13
 
suggested a possible link between colorectal neuro-
endocrine carcinoma and adenocarcinoma. These 
reports are consistent with the findings in our case 
where the patient had an advanced stage of 
neuroendocrine carcinoma in the caecum and a 
synchronous adenocarcinoma in the rectum. It is 
possible that the neuroendocrine caercinoma was 
associated with the development of the adeno-
carcinoma of the rectum. However, further confir-
mation is needed to support this. 
For colonic neuroendocrine tumours (excluding 
appendiceal tumours), 5-year survival rates are 76.0% 
for localized disease, 71.6% for regional disease, and 
30.0% for tumours with distant metastases. Overall, 
the 5-year survival rate is 61.8%.
14
 If the 
neuroendocrine carcinoma is completely resected, the 
5-year survival rate has been reported to be 61%.
15
 
However, most patients are not candidates for 
curative resection. 
After completely resection both of the tumours, 
our patient received systemic chemotherapy with 5-
fluorouracil. 5-fluorouracil is the chemotherapeutic 
agent of first choice in the treatment of patients with 
colorectal cancer. Five cycles of systemic chemo-
therapy were provided. The patient is still alive with 
good performance status and no sign of tumour 
progression. 
In conclusion, we report a SCNEC of the caecum 
that coexisted with an adenocarcinoma, suggesting 
possible association between colorectal neuroendo-
crine carcinoma and adenocarcinoma. Further investi-
gations are required to determine the pathogenesis of 
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